OmniAb Inc.
$ 1.64
5.13%
17 Apr - close price
- Market Cap 237,444,000 USD
- Current Price $ 1.64
- High / Low $ 1.65 / 1.55
- Stock P/E N/A
- Book Value 1.85
- EPS -0.57
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.23 %
- 52 Week High 2.29
- 52 Week Low 1.22
About
OmniAb Inc. is a pioneering biotechnology firm focused on the creation of fully human therapeutic antibodies through its cutting-edge OmniAb platform. This unique technology facilitates the rapid discovery and refinement of high-efficacy therapeutics to tackle a diverse range of diseases. By fostering strategic partnerships and collaborations, OmniAb strives to expedite drug development and broaden access to innovative therapies. With an experienced leadership team and a strong product pipeline, the company is well-positioned to seize expanding opportunities within the biopharmaceutical landscape.
Analyst Target Price
$7.33
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-05 | 2025-11-04 | 2025-08-06 | 2025-05-07 | 2025-03-18 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-03-20 | 2023-11-09 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.11 | -0.14 | -0.15 | -0.17 | -0.12 | -0.16 | -0.13 | -0.19 | -0.14 | -0.16 | -0.15 | -0.08 |
| Estimated EPS | -0.0875 | -0.13 | -0.13 | -0.1667 | -0.0967 | -0.14 | -0.17 | -0.16 | -0.15 | -0.14 | -0.12 | -0.03 |
| Surprise | -0.0225 | -0.01 | -0.02 | -0.0033 | -0.0233 | -0.02 | 0.04 | -0.03 | 0.01 | -0.02 | -0.03 | -0.05 |
| Surprise Percentage | -25.7143% | -7.6923% | -15.3846% | -1.9796% | -24.0951% | -14.2857% | 23.5294% | -18.75% | 6.6667% | -14.2857% | -25% | -166.6667% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.1 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OABI
2026-04-19 02:09:51
This is the Q3 2025 earnings call transcript for OmniAb, Inc. (NASDAQ:OABI). The content provided is likely a detailed record of the company's financial performance, operational highlights, and future outlook as discussed by management during the call. Investors and analysts would typically review such transcripts for in-depth insights into the company's business.
2026-04-18 14:40:38
This article is an earnings call transcript for OmniAb, Inc. (NASDAQ:OABI) for the third quarter of 2025. It would typically contain discussions on financial performance, future outlook, and Q&A with analysts and management.
2026-04-14 12:10:46
This article provides financial information for OmniAb, Inc. (NASDAQ: OABIW), specifically focusing on its working capital per share, as presented on TradingView. The page indicates that the market is currently closed and provides general financial data and tools available on the platform.
2026-04-09 05:10:17
OmniAb director Matthew W. Foehr sold 19,244 shares of common stock for approximately $28,673. Despite this, he also acquired a significant number of shares and restricted stock units, now directly owning over 4.4 million shares and 309,376 RSUs. The company recently reported a decrease in Q4 2025 revenues and a net loss, but analysts maintain a positive outlook and "Strong Buy" consensus, citing growth in active partners and programs.
2026-04-08 17:39:14
OmniAb's Chief Legal Officer, Charles S. Berkman, sold 7,157 shares of common stock for a total of $10,663, while also exercising options for 13,542 shares at $0. This occurred as the stock is down 18% year-to-date and is considered slightly overvalued. Despite recent financial challenges, such as decreased revenues and a net loss, analysts have reiterated Buy ratings, citing growth in partnerships and positive sector developments.
2026-04-08 17:39:14
OmniAb, Inc. Director Matthew W. Foehr sold 19,244 shares of common stock for approximately $28,673 on April 7, 2026. Despite this sale and a year-to-date stock decline, Foehr still directly owns over 4.4 million shares and 309,376 Restricted Stock Units after also acquiring and converting shares. Analysts maintain a "strong buy" consensus on OABI, with several firms reiterating positive outlooks and price targets despite recent revenue declines, based on increasing active partners and programs.
